StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) stock

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

COSCIENS Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

COSCIENS Biopharma's operating income for the twelve months ending Mar 31, 2026 was -$7.79M. For fiscal 2025 it was -$10.68M. The highest annual figure on record is $9.84M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.68M–
FY2024Dec 31, 2024-$18.28M–
FY2023Dec 31, 2023-$4.63M-207.2%
FY2022Dec 31, 2022$4.32M–
FY2021Dec 31, 2021-$8.67M–
FY2020Dec 31, 2020-$5.71M–
FY2019Dec 31, 2019-$10.24M-204.1%
FY2018Dec 31, 2018$9.84M–
FY2017Dec 31, 2017-$23.07M–
FY2016Dec 31, 2016-$29.48M–
FY2015Dec 31, 2015-$34.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$730.00K–
Q4 FY2025Dec 31, 2025-$2.39M–
Q3 FY2025Sep 30, 2025-$2.32M–
Q2 FY2025Jun 30, 2025-$2.35M–
Q1 FY2025Mar 31, 2025-$2.66M–
Q4 FY2024Dec 31, 2024-$6.41M–
Q3 FY2024Sep 30, 2024-$6.29M–
Q2 FY2024Jun 30, 2024-$3.76M–
Q1 FY2024Mar 31, 2024-$1.81M–
Q4 FY2023Dec 31, 2023-$2.04M-113.1%
Q3 FY2023Sep 30, 2023-$1.11M–
Q2 FY2023Jun 30, 2023-$1.11M–
Q1 FY2023Mar 31, 2023-$4.21M–
Q4 FY2022Dec 31, 2022$15.57M–
Q3 FY2022Sep 30, 2022-$3.72M–
Q2 FY2022Jun 30, 2022-$4.72M–
Q1 FY2022Mar 31, 2022-$2.81M–
Q4 FY2021Dec 31, 2021-$3.13M–
Q3 FY2021Sep 30, 2021-$2.05M–
Q2 FY2021Jun 30, 2021-$2.16M–
Q1 FY2021Mar 31, 2021-$1.33M–
Q4 FY2020Dec 31, 2020-$1.25M–
Q3 FY2020Sep 30, 2020-$1.74M–
Q2 FY2020Jun 30, 2020-$1.44M–
Q1 FY2020Mar 31, 2020-$1.28M–
Q4 FY2019Dec 31, 2019-$1.76M–
Q3 FY2019Sep 30, 2019-$1.81M–
Q2 FY2019Jun 30, 2019-$3.73M–
Q1 FY2019Mar 31, 2019-$2.94M–
Q4 FY2018Dec 31, 2018-$3.04M–
Q3 FY2018Sep 30, 2018-$3.01M–
Q2 FY2018Jun 30, 2018-$3.50M–

More COSCIENS Biopharma figures

See a number that looks wrong?